Form 10-Q · Quarterly report
Regeneron Pharmaceuticals 10-Q, filed Jul 30, 2026
- Filed
- CIK
- 0000872589
- Accession no.
- 0000872589-26-000025
Summary
Regeneron Pharmaceuticals reported second-quarter 2026 revenues of $4.29 billion, up from $3.68 billion a year earlier, while net income fell to $1.30 billion from $1.39 billion. The company also said EYLEA HD received European Commission approval for retinal vein occlusion and FDA approval for extended dosing intervals up to 20 weeks in wet age-related macular degeneration and diabetic macular edema.
Key points
- Second-quarter 2026 revenue rose to $4.29 billion from $3.68 billion a year earlier; net income was $1.30 billion, or $12.23 per diluted share, versus $1.39 billion and $12.81.
- Dupixent global net product sales rose 38% to $6.00 billion in the second quarter of 2026.
- Combined EYLEA HD and EYLEA net product sales fell 21% to $1.68 billion in the second quarter of 2026.
- EYLEA HD was approved by the European Commission for retinal vein occlusion and by the FDA for extended dosing intervals up to 20 weeks in wet age-related macular degeneration and diabetic macular edema.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management's Discussion Overview Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.